1. Home
  2. TNXP vs LAES Comparison

TNXP vs LAES Comparison

Compare TNXP & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$18.47

Market Cap

231.3M

Sector

Health Care

ML Signal

HOLD

Logo SEALSQ Corp

LAES

SEALSQ Corp

HOLD

Current Price

$4.15

Market Cap

366.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
LAES
Founded
2007
2022
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
231.3M
366.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TNXP
LAES
Price
$18.47
$4.15
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$70.00
$6.50
AVG Volume (30 Days)
639.5K
12.0M
Earning Date
11-10-2025
12-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,299,000.00
$10,978,000.00
Revenue This Year
$14.79
N/A
Revenue Next Year
$933.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.76
$1.98
52 Week High
$72.00
$11.00

Technical Indicators

Market Signals
Indicator
TNXP
LAES
Relative Strength Index (RSI) 51.32 43.93
Support Level $17.71 $3.87
Resistance Level $19.70 $4.30
Average True Range (ATR) 1.27 0.37
MACD 0.19 -0.03
Stochastic Oscillator 62.64 23.98

Price Performance

Historical Comparison
TNXP
LAES

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.

Share on Social Networks: